High-resolution microendoscopy for esophageal cancer screening in China: A cost-effectiveness analysis
Year: 2015
Type: article
Abstract: AIM: To study the cost-effectiveness of high-resolution microendoscopy (HRME) in an esophageal squamous cell carcinoma (ESCC) screening program in China. METHODS: A decision analytic Markov model of ESCC was developed. Separate model analyses were conducted for cohorts consisting of an average-risk population or a high-risk population in China. Hypothetical 50-year-old individuals were followed until age 80 or death. We compared three different strategies for both cohorts: (1) no screening; (2) standard endoscopic screening with Lugol's iodine staining; and (3) endoscopic screening with Lugol's iodine staining and an HRME. Model parameters were estimated from the literature as well as from GLOBOCAN, the Cancer Incidence and Mortality Worldwide cancer database. Health states in the model included non-neoplasia, mild dysplasia, moderate dysplasia, high-grade dysplasia, intramucosal carcinoma, operable cancer, inoperable cancer, and death. Separate ESCC incidence transition rates were generated for the average-risk and high-risk populations. Costs in Chinese currency were converted to international dollars (I$) and were adjusted to 2012 dollars using the Consumer Price Index. RESULTS: The main outcome measurements for this study were quality-adjusted life years (QALYs) and incremental cost-effectiveness ratio (ICER). For the average-risk population, the HRME screening strategy produced 0.043 more QALYs than the no screening strategy at an additional cost of I$646, resulting in an ICER of I$11808 per QALY gained. Standard endoscopic screening was weakly dominated. Among the high-risk population, when the HRME screening strategy was compared with the standard screening strategy, the ICER was I$8173 per QALY. For both the high-risk and average-risk screening populations, the HRME screening strategy appeared to be the most cost-effective strategy, producing ICERs below the willingness-to-pay threshold, I$23500 per QALY. One-way sensitivity analysis showed that, for the average-risk population, higher specificity of Lugol's iodine (> 40%) and lower specificity of HRME (< 70%) could make Lugol's iodine screening cost-effective. For the high-risk population, the results of the model were not substantially affected by varying the follow-up rate after Lugol's iodine screening, Lugol's iodine test characteristics (sensitivity and specificity), or HRME specificity. CONCLUSION: The incorporation of HRME into an ESCC screening program could be cost-effective in China. Larger studies of HRME performance are needed to confirm these findings.
Institution: Massachusetts General Hospital
Language: English
Subfield: Surgery
Field: Medicine
Domain: Health Sciences
Keywords: high-resolution microendoscopy, esophageal squamous cell carcinoma, cancer screening, cost-effectiveness, Lugol's iodine staining, endoscopic screening, dysplasia, quality-adjusted life years, incremental cost-effectiveness ratio, vulnerable populations, China, screening strategy comparison, follow-up after screening, Markov decision-analytic model
Open Access status: hybrid
Funder: National Cancer Institute
Awards: Improving Esophageal Adenocarcinoma Prevention, Screening and Treatment, Applications of Multi-Criteria Optimization (AMCO) to Cancer Simulation Modeling, High Resolution Microendoscopy for the Detection of Esophageal Neoplasia, Controlling Esophageal Cancer in the US.: A Colloraborative Modeling Project, AI-Assisted Microendoscopy for the Early Detection of Esophageal Cancer
OpenAlex ID: W2337568552
